IP Library Granted Patent US 7,763,437
Granted Patent B1
US 7,763,437 · App. 11/482,277 · Granted Jul 27, 2010

Methods for identifying compounds that regulate β-Arrestin signaling complexes

Assignee: Duke University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,437
App. No.
11/482,277
Granted
Jul 27, 2010
Kind
B1
Abstract

A method of screening a candidate compound for βArrestin mediated anti-G protein coupled receptor signaling activity is comprises: (a) contacting said candidate compound to a βArrestin signaling complex or a constituent thereof, under conditions in which a signaling complex is formed; and then (b) detecting the presence or absence of disruption of said signaling complex, disruption of said complex indicating said compound has βArrestin mediated anti-G protein coupled receptor signaling activity. Compositions and kits for carrying out the method are also described.

Claims (10)

1. A method of screening a candidate compound for anti-βArrestin-2 mediated G protein coupled receptor signaling activity, comprising:

(a) contacting said candidate compound to a βArrestin-2 signaling complex or a constituent thereof, said signaling complex comprising as constituents βArrestin 2, Akt and PP2A, under conditions in which a signaling complex of said constituents is formed in the absence of said candidate compound; and then

(b) detecting the presence or absence of disruption of a said signaling complex, disruption of said complex indicating said compound has anti-βArrestin-2 mediated G protein coupled receptor signaling activity.

2. The method of claim 1 , wherein said contacting step is carried out in vitro.

3. The method of claim 1 , wherein said contacting step is carried out in a heterologous cell system.

4. The method of claim 1 , wherein said contacting step is carried out in vivo in mammalian cells, and wherein said cells are grown in culture or a host animal.

5. The method of claim 4 , wherein said cells are central nerve cells, peripheral nerve cells, skin cells, gastrointestinal cells, muscle cells, vascular cells, lymphocytes, neutrophils, macrophages, fibroblasts, tumor cells, osteoblasts and osteocytes.

6. The method of claim 1 , wherein said detecting step is carried out in vitro or in vivo.

7. The method of claim 1 , wherein said anti-G protein coupled receptor signaling activity is selected from the group consisting of anticancer, antidopaminergic, antiserotoninergic, antimuscarinic, antiadrenergic, anti-peptide hormone signaling and antiopiate activity.

8. The method of claim 1 , wherein said anti-G protein coupled receptor signaling activity is anti-peptide hormone signaling activity selected from the group consisting of angiotensin and vasopressin signaling activity.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 20, 2018
From: DUKE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046438/0119 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2006
From: CARON, MARC G.; BEAULIEU, MARTIN; GAINETDINOV, RAUL R.; SOTNIKOVA, TATIANA D.; MARION, SEBASTIEN
To: DUKE UNIVERSITY
Reel/Frame 018168/0857 →
Continuity (1)
Provisional Application 6069965100 · Jul 15, 2005